20/20 GeneSystems is developing what we believe will be the first routine blood test for the #1 cancer killer.
As described in a report published last year in the Journal of Thoracic Oncology 2020's multi-biomarker blood test -- exclusiveiy licensed to us from the University of Kentucky--appears able to detect non-small cell lung cancer (NSCLC) significantly earlier than CT scanning. This builds on  work detailed  in a 2005 article.
Other News

20/20 Licences lung cancer test to Ortho-Clinical Diagnostics

20/20 Wins $2M ATP award

20/20 Awarded $150,000 by Johnson & Johnson and TEDCO investment program

 

 

BioDefense

20/20's profitable business unit 20/20 BioResponse feartures the BioCheckTM Suspicious Powder Screening Test Kit

Oncology

Multiplex tests for early detetion and guiding of personalized cancer treatements

Autoimmune Disease

LGS solutions for monitoring patient response to therapy for Lupus and other diseases